Operaciones Teva Pharma Ind Adr Rep 1 - TEVA CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.09 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.030779% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | -0.013666% | ||||||||
| Horario tarifa nocturna | 22:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Teva Pharmaceutical Industries Ltd ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 10.67 |
| Abrir* | 10.66 |
| Cambio de 1 año* | 25.56% |
| Rango del día* | 10.64 - 10.73 |
| Rango de 52 semanas | 6.78-11.45 |
| Volumen medio (10 días) | 8.25M |
| Volumen medio (3 meses) | 194.23M |
| Capitalización de mercado | 11.79B |
| Ratio P/E | -100.00K |
| Acciones en circulación | 1.11B |
| Ingresos | 15.14B |
| EPS | -1.17 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 1.21 |
| Próxima fecha de resultados | Feb 8, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Feb 6, 2023 | 10.68 | 0.00 | 0.00% | 10.68 | 10.74 | 10.61 |
| Feb 3, 2023 | 10.67 | 0.16 | 1.52% | 10.51 | 10.76 | 10.51 |
| Feb 2, 2023 | 10.66 | 0.09 | 0.85% | 10.57 | 10.68 | 10.47 |
| Feb 1, 2023 | 10.56 | 0.11 | 1.05% | 10.45 | 10.64 | 10.35 |
| Jan 31, 2023 | 10.39 | 0.18 | 1.76% | 10.21 | 10.67 | 10.21 |
| Jan 30, 2023 | 10.21 | 0.07 | 0.69% | 10.14 | 10.36 | 10.05 |
| Jan 27, 2023 | 10.24 | 0.10 | 0.99% | 10.14 | 10.48 | 10.14 |
| Jan 26, 2023 | 10.23 | 0.09 | 0.89% | 10.14 | 10.27 | 10.07 |
| Jan 25, 2023 | 10.15 | 0.11 | 1.10% | 10.04 | 10.19 | 10.02 |
| Jan 24, 2023 | 10.05 | -0.16 | -1.57% | 10.21 | 10.32 | 10.05 |
| Jan 23, 2023 | 10.33 | 0.02 | 0.19% | 10.31 | 10.43 | 10.20 |
| Jan 20, 2023 | 10.21 | -0.30 | -2.85% | 10.51 | 10.59 | 10.21 |
| Jan 19, 2023 | 10.47 | 0.00 | 0.00% | 10.47 | 10.62 | 10.23 |
| Jan 18, 2023 | 10.80 | 0.00 | 0.00% | 10.80 | 10.90 | 10.68 |
| Jan 17, 2023 | 10.95 | -0.15 | -1.35% | 11.10 | 11.21 | 10.92 |
| Jan 13, 2023 | 11.18 | -0.01 | -0.09% | 11.19 | 11.27 | 10.94 |
| Jan 12, 2023 | 11.26 | 0.19 | 1.72% | 11.07 | 11.41 | 11.02 |
| Jan 11, 2023 | 10.96 | 0.02 | 0.18% | 10.94 | 11.14 | 10.82 |
| Jan 10, 2023 | 10.88 | 0.06 | 0.55% | 10.82 | 11.01 | 10.75 |
| Jan 9, 2023 | 10.78 | -0.05 | -0.46% | 10.83 | 11.19 | 10.58 |
Teva Pharma Ind Adr Rep 1 Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Ingresos totales | 21903 | 22385 | 18854 | 16887 | 16659 | 15878 |
| Ingresos | 21903 | 22385 | 18854 | 16887 | 16659 | 15878 |
| Coste de los ingresos, total | 10250 | 11770 | 10558 | 9351 | 8870 | 8014 |
| Beneficio bruto | 11653 | 10615 | 8296 | 7536 | 7789 | 7864 |
| Gastos totales de explotación | 20631 | 39911 | 20537 | 17330 | 20231 | 14162 |
| Gastos de venta/general/administración Gastos, total | 4973 | 4637 | 4052 | 3667 | 3519 | 3402 |
| Investigación y desarrollo | 2077 | 1778 | 1213 | 1010 | 997 | 967 |
| Gastos (ingresos) extraordinarios | 3286 | 21520 | 4838 | 3191 | 6739 | 1721 |
| Other Operating Expenses, Total | 45 | -3 | -286 | -28 | -20 | -41 |
| Ingresos de explotación | 1272 | -17526 | -1683 | -443 | -3572 | 1716 |
| Ingresos por intereses (gastos), netos No operativos | -446 | -856 | -894 | -825 | -833 | -988 |
| Otros, netos | -2 | 3 | -19 | 3 | -1 | -70 |
| Ingresos netos antes de impuestos | 824 | -18379 | -2596 | -1265 | -4406 | 658 |
| Ingresos netos después de impuestos | 303 | -17507 | -2304 | -987 | -4238 | 447 |
| Intereses menores | 18 | 184 | 322 | 2 | 109 | -39 |
| Equity In Affiliates | 8 | -3 | -71 | -13 | 138 | 9 |
| Beneficio neto antes de partidas extra. Elementos | 329 | -17326 | -2053 | -998 | -3991 | 417 |
| Total de partidas extraordinarias | 0 | 1061 | -97 | 0 | 0 | |
| Ingresos netos | 329 | -16265 | -2150 | -998 | -3991 | 417 |
| Total Adjustments to Net Income | -261 | -260 | -249 | -1 | 1 | |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 68 | -17586 | -2302 | -999 | -3990 | 417 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 68 | -16525 | -2399 | -999 | -3990 | 417 |
| Ajuste por dilución | 0 | |||||
| Beneficio neto diluido | 68 | -16525 | -2399 | -999 | -3990 | 417 |
| Promedio ponderado de acciones diluidas | 961 | 1016 | 1021 | 1091 | 1095 | 1107 |
| BPA diluido sin partidas extraordinarias | 0.07076 | -17.3091 | -2.25465 | -0.91567 | -3.64384 | 0.37669 |
| Dividends per Share - Common Stock Primary Issue | 1.36 | 0.85 | 0 | |||
| BPA normalizado diluido | 2.29537 | -3.51127 | 0.82537 | 0.98547 | 0.35648 | 1.43282 |
| Depreciation / Amortization | 209 | 162 | 139 | 126 | 99 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 3982 | 3910 | 3887 | 4100 | 3661 |
| Ingresos | 3982 | 3910 | 3887 | 4100 | 3661 |
| Coste de los ingresos, total | 2063 | 1987 | 1989 | 1975 | 1859 |
| Beneficio bruto | 1919 | 1923 | 1898 | 2125 | 1802 |
| Gastos totales de explotación | 3548 | 3328 | 3264 | 4022 | 4374 |
| Gastos de venta/general/administración Gastos, total | 848 | 832 | 864 | 858 | 819 |
| Investigación y desarrollo | 254 | 243 | 222 | 249 | 225 |
| Depreciation / Amortization | 27 | 25 | 24 | 23 | 22 |
| Gastos (ingresos) extraordinarios | 360 | 247 | 183 | 893 | 1502 |
| Other Operating Expenses, Total | -4 | -6 | -18 | 24 | -53 |
| Ingresos de explotación | 434 | 582 | 623 | 78 | -713 |
| Ingresos por intereses (gastos), netos No operativos | -381 | -254 | -254 | -170 | -238 |
| Otros, netos | 91 | -20 | 13 | -83 | -20 |
| Ingresos netos antes de impuestos | 144 | 308 | 382 | -175 | -971 |
| Ingresos netos después de impuestos | 82 | 210 | 306 | -151 | -973 |
| Intereses menores | -7 | -14 | -11 | -7 | -3 |
| Equity In Affiliates | 3 | 11 | -5 | 0 | 21 |
| Beneficio neto antes de partidas extra. Elementos | 78 | 207 | 290 | -158 | -955 |
| Ingresos netos | 78 | 207 | 290 | -158 | -955 |
| Total Adjustments to Net Income | -1 | 2 | -1 | ||
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 77 | 207 | 292 | -159 | -955 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 77 | 207 | 292 | -159 | -955 |
| Beneficio neto diluido | 77 | 207 | 292 | -159 | -955 |
| Promedio ponderado de acciones diluidas | 1107 | 1109 | 1109 | 1102 | 1107 |
| BPA diluido sin partidas extraordinarias | 0.06956 | 0.18665 | 0.2633 | -0.14428 | -0.86269 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | 0.25474 | 0.33851 | 0.39548 | 0.38244 | 0.01924 |
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Activo Corriente | 17228 | 15382 | 13794 | 13464 | 13005 | 12573 |
| Efectivo e inversiones a corto plazo | 1667 | 977 | 1784 | 1975 | 2177 | 2165 |
| Efectivo y Equivalentes | 988 | 963 | 1782 | 1975 | 2177 | 2165 |
| Inversiones a corto plazo | 679 | 14 | 2 | |||
| Total deudores, neto | 7523 | 7128 | 5822 | 5676 | 4581 | 4529 |
| Accounts Receivable - Trade, Net | 7523 | 7128 | 5822 | 5676 | 4581 | 4529 |
| Total Inventory | 4954 | 4924 | 4731 | 4422 | 4403 | 3818 |
| Prepaid Expenses | 1629 | 1100 | 899 | 870 | 945 | 1075 |
| Other Current Assets, Total | 1455 | 1253 | 558 | 521 | 899 | 986 |
| Total Assets | 93057 | 70615 | 60683 | 57470 | 50640 | 47666 |
| Property/Plant/Equipment, Total - Net | 8073 | 7673 | 6868 | 6950 | 6855 | 6477 |
| Property/Plant/Equipment, Total - Gross | 11926 | 12178 | 11796 | 11864 | 11947 | 11718 |
| Accumulated Depreciation, Total | -3853 | -4505 | -4928 | -4914 | -5092 | -5241 |
| Goodwill, Net | 44409 | 28414 | 24917 | 24846 | 20624 | 20040 |
| Intangibles, Net | 21487 | 17640 | 14005 | 11232 | 8923 | 7466 |
| Other Long Term Assets, Total | 1860 | 1423 | 1038 | 978 | 1233 | 1110 |
| Total Current Liabilities | 18488 | 17921 | 14322 | 13674 | 13164 | 11027 |
| Accounts Payable | 2157 | 2069 | 1853 | 1718 | 1756 | 1686 |
| Accrued Expenses | 4264 | 3563 | 2738 | 2680 | 2581 | 2880 |
| Notes Payable/Short Term Debt | 2466 | 766 | 516 | 514 | 514 | 23 |
| Current Port. of LT Debt/Capital Leases | 810 | 2880 | 1700 | 1831 | 2674 | 1403 |
| Other Current Liabilities, Total | 8791 | 8643 | 7515 | 6931 | 5639 | 5035 |
| Total Liabilities | 59720 | 53256 | 45976 | 43498 | 40614 | 37388 |
| Total Long Term Debt | 32522 | 28827 | 26691 | 24562 | 22731 | 21617 |
| Long Term Debt | 32522 | 28827 | 26691 | 24562 | 22731 | 21617 |
| Deferred Income Tax | 5413 | 3277 | 2140 | 1096 | 964 | 784 |
| Minority Interest | 1656 | 1386 | 1087 | 1091 | 1035 | 966 |
| Other Liabilities, Total | 1641 | 1845 | 1736 | 3075 | 2720 | 2994 |
| Total Equity | 33337 | 17359 | 14707 | 13972 | 10026 | 10278 |
| Redeemable Preferred Stock | 3620 | 3631 | 0 | |||
| Common Stock | 54 | 54 | 56 | 56 | 57 | 57 |
| Additional Paid-In Capital | 23409 | 23479 | 27210 | 27312 | 27443 | 27561 |
| Retained Earnings (Accumulated Deficit) | 13607 | -3803 | -5958 | -6956 | -10946 | -10529 |
| Treasury Stock - Common | -4194 | -4149 | -4142 | -4128 | -4128 | -4128 |
| Unrealized Gain (Loss) | -7 | -4 | 1 | 0 | 0 | 0 |
| Other Equity, Total | -3152 | -1849 | -2460 | -2312 | -2400 | -2683 |
| Total Liabilities & Shareholders’ Equity | 93057 | 70615 | 60683 | 57470 | 50640 | 47666 |
| Total Common Shares Outstanding | 1014.99 | 1016.88 | 1089.39 | 1092.19 | 1096.51 | 1103.33 |
| Total Preferred Shares Outstanding | 3.7 | 3.7 | 0 | 0 | 0 | |
| Long Term Investments | 83 | 61 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 12401 | 12822 | 12154 | 12573 | 12451 |
| Efectivo e inversiones a corto plazo | 1743 | 2436 | 2045 | 2165 | 2175 |
| Efectivo y Equivalentes | 1743 | 2436 | 2045 | 2165 | 2175 |
| Total deudores, neto | 4572 | 4488 | 4046 | 4529 | 4253 |
| Accounts Receivable - Trade, Net | 4572 | 4488 | 4046 | 4529 | 4253 |
| Total Inventory | 4406 | 4362 | 4167 | 3818 | 4012 |
| Prepaid Expenses | 942 | 1022 | 1066 | 1075 | 1064 |
| Other Current Assets, Total | 738 | 514 | 830 | 986 | 947 |
| Total Assets | 49004 | 49195 | 47851 | 47666 | 47059 |
| Property/Plant/Equipment, Total - Net | 6641 | 6658 | 6547 | 6477 | 6396 |
| Goodwill, Net | 20302 | 20421 | 20179 | 20040 | 19986 |
| Intangibles, Net | 8445 | 8120 | 7832 | 7466 | 7116 |
| Other Long Term Assets, Total | 1215 | 1174 | 1139 | 1110 | 1110 |
| Total Current Liabilities | 12089 | 12691 | 11825 | 11027 | 11613 |
| Accounts Payable | 1692 | 1551 | 1514 | 1686 | 1750 |
| Accrued Expenses | 2377 | 2318 | 2590 | 2771 | 3078 |
| Notes Payable/Short Term Debt | 23 | 23 | 323 | 23 | 23 |
| Current Port. of LT Debt/Capital Leases | 2674 | 3507 | 2386 | 1403 | 2054 |
| Other Current Liabilities, Total | 5323 | 5292 | 5012 | 5144 | 4708 |
| Total Liabilities | 39004 | 38871 | 37384 | 37388 | 37715 |
| Total Long Term Debt | 22288 | 21602 | 21037 | 21617 | 20840 |
| Long Term Debt | 22288 | 21602 | 21037 | 21617 | 20840 |
| Deferred Income Tax | 991 | 932 | 910 | 784 | 666 |
| Minority Interest | 975 | 987 | 984 | 966 | 916 |
| Other Liabilities, Total | 2661 | 2659 | 2628 | 2994 | 3680 |
| Total Equity | 10000 | 10324 | 10467 | 10278 | 9344 |
| Common Stock | 57 | 57 | 57 | 57 | 57 |
| Additional Paid-In Capital | 27474 | 27503 | 27529 | 27561 | 27587 |
| Retained Earnings (Accumulated Deficit) | -10869 | -10662 | -10370 | -10529 | -11484 |
| Treasury Stock - Common | -4128 | -4128 | -4128 | -4128 | -4128 |
| Other Equity, Total | -2534 | -2446 | -2621 | -2683 | -2688 |
| Total Liabilities & Shareholders’ Equity | 49004 | 49195 | 47851 | 47666 | 47059 |
| Total Common Shares Outstanding | 1102.35 | 1102.89 | 1103.01 | 1103.33 | 1110.35 |
| Total Preferred Shares Outstanding | 0 | ||||
| Unrealized Gain (Loss) | 0 |
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | 311 | -16449 | -2472 | -1000 | -4099 | 456 |
| Efectivo de actividades de explotación | 3890 | 2225 | 2446 | 748 | 1216 | 798 |
| Efectivo de actividades de explotación | 1524 | 2112 | 1842 | 1722 | 1557 | 1330 |
| Deferred Taxes | 15 | -2331 | -837 | -985 | -696 | -120 |
| Partidas no monetarias | 2156 | 20538 | 5736 | 1907 | 6642 | 833 |
| Cash Taxes Paid | 341 | 106 | 420 | 552 | 709 | 495 |
| Intereses pagados en efectivo | 290 | 795 | 815 | 840 | 846 | 913 |
| Cambios en el capital circulante | -116 | -1645 | -1823 | -896 | -2188 | -1701 |
| Efectivo de actividades de inversión | -34405 | 3446 | 1866 | 1355 | 863 | 1523 |
| Gastos de capital | -901 | -874 | -651 | -525 | -578 | -562 |
| Otras partidas de flujo de caja de inversión, total | -33504 | 4320 | 2517 | 1880 | 1441 | 2085 |
| Efectivo procedente de actividades de financiación | 25217 | -5750 | -3351 | -1926 | -1885 | -2172 |
| Elementos de flujo de caja de financiación | -169 | -112 | -57 | -11 | -5 | -6 |
| Total Cash Dividends Paid | -1558 | -1161 | -22 | -52 | 0 | 0 |
| Emisión (retiro) de acciones, neto | 693 | 0 | 0 | |||
| Emisión (amortización) de deuda, neta | 26251 | -4477 | -3272 | -1863 | -1880 | -2166 |
| Efectos del cambio de divisas | -660 | 54 | -142 | 16 | 8 | -128 |
| Variación neta de la tesorería | -5958 | -25 | 819 | 193 | 202 | 21 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 84 | 306 | 608 | 456 | -952 |
| Cash From Operating Activities | -405 | -187 | 342 | 798 | -49 |
| Cash From Operating Activities | 376 | 681 | 1010 | 1330 | 323 |
| Deferred Taxes | -11 | 5 | 13 | -120 | -175 |
| Non-Cash Items | 222 | 500 | 592 | 833 | 196 |
| Changes in Working Capital | -1076 | -1679 | -1881 | -1701 | 559 |
| Cash From Investing Activities | 508 | 989 | 1277 | 1523 | 161 |
| Capital Expenditures | -150 | -263 | -409 | -562 | -157 |
| Other Investing Cash Flow Items, Total | 658 | 1252 | 1686 | 2085 | 318 |
| Cash From Financing Activities | -493 | -494 | -1671 | -2172 | 2 |
| Financing Cash Flow Items | -2 | -3 | -5 | -6 | 2 |
| Issuance (Retirement) of Debt, Net | -491 | -491 | -1666 | -2166 | 0 |
| Foreign Exchange Effects | -44 | -49 | -80 | -128 | -62 |
| Net Change in Cash | -434 | 259 | -132 | 21 | 52 |
| Total Cash Dividends Paid | 0 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Capital Research Global Investors | Investment Advisor | 10.5524 | 117190328 | 24024045 | 2022-09-30 | LOW |
| Capital World Investors | Investment Advisor | 3.5415 | 39329765 | 39329765 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.8455 | 31600577 | -827744 | 2022-09-30 | LOW |
| Abrams Capital, L.L.C. | Hedge Fund | 2.152 | 23899296 | -147060 | 2022-09-30 | |
| Menora Mivtachim Insurance Ltd. | Insurance Company | 2.0987 | 23307560 | -3050 | 2022-09-30 | LOW |
| Migdal Insurance and Financial Holdings Ltd | Insurance Company | 1.9447 | 21596560 | 216360 | 2022-12-31 | MED |
| Phoenix Holdings Ltd | Holding Company | 1.8757 | 20831080 | 2301291 | 2022-09-30 | MED |
| Clal Insurance Enterprises Holdings Ltd. | Investment Advisor | 1.7475 | 19406766 | 444000 | 2022-09-30 | LOW |
| Harel Insurance Investments and Financial Services Ltd | Investment Advisor | 1.3613 | 15118229 | 985502 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.3418 | 14901933 | 1055920 | 2022-09-30 | LOW |
| EXOR Investments (UK) LLP | Investment Advisor | 1.0375 | 11522187 | 11522187 | 2022-09-30 | LOW |
| Capital International Investors | Investment Advisor | 0.9613 | 10675231 | -7647 | 2022-09-30 | LOW |
| Miller Value Partners, LLC | Investment Advisor | 0.8334 | 9254875 | -79715 | 2022-09-30 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7338 | 8148857 | 126299 | 2022-09-30 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.7189 | 7983801 | 5844332 | 2022-09-30 | HIGH |
| Beck, Mack & Oliver LLC | Investment Advisor | 0.6787 | 7536985 | 1072190 | 2022-09-30 | LOW |
| Camber Capital Management LP | Hedge Fund | 0.6753 | 7500000 | 4750000 | 2022-09-30 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5973 | 6633114 | 314715 | 2022-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.4259 | 4730246 | -881152 | 2022-09-30 | LOW |
| Schweizerische Nationalbank | Bank and Trust | 0.4247 | 4716093 | 27700 | 2022-09-30 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group +485000+
Traders
65000+
Clientes activos mensualmente
$48000000+
Volumen mensual de inversión
$28000000+
Pruébalo ahora Retiros por mes
Calculadora de trading
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Comisión de la operación
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Apalancamiento
20:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Teva Company profile
Sobre Teva Pharmaceutical Industries Ltd (ADR)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED es una compañía farmacéutica global. La empresa se dedica al desarrollo, producción y comercialización de medicamentos genéricos y una cartera de medicamentos de especialidad. La compañía opera a través de dos segmentos: Medicamentos genéricos y medicamentos de especialidad. Tiene una cartera de aproximadamente 1.000 moléculas. Su cartera de sistema nervioso central (SNC) incluye Copaxone para el tratamiento de la esclerosis múltiple, Azilect para el tratamiento de los síntomas de la enfermedad de Parkinson y Nuvigil para el tratamiento de trastornos del sueño, así como varias terapias para el tratamiento del dolor. Sus principales medicamentos respiratorios incluyen hidrofluoroalcano ProAir, QVAR y Duoresp Spiromax. Su cartera de Oncología incluye Treanda, Trisenox, Granix Synribo en Estados Unidos y Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox y Eporatio fuera de Estados Unidos. Su cartera de salud de la mujer incluye ParaGard, Plan B One-Step (levonorgestrel) de venta libre y con receta y Zoely.
- IndustriaPharmaceuticals (NEC)
- Dirección5 Bazel St, P O B 3190, PETAH TIKVA, Israel (ISR)
- Empleados37037
- CEOKaare Schultz
| Industry: | Pharmaceuticals (NEC) |
5 Bazel St
P O B 3190
PETAH TIKVA
49131
IL
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 485.000 traders de todo el mundo que eligen operar con Capital.com